Tag: iPSCs

Exogenously delivered iPSCs disrupt the natural repair response of endogenous MPCs after bone injury

Ethics statement All animal studies were performed in accordance with the recommendations in the Canadian Council on Animal Care Guidelines. The reporting of this data in the manuscript follows the recommendations in the ARRIVE guidelines. The University of Calgary Health Sciences Animal Care Committee approved all animal protocols and surgical…

Continue Reading Exogenously delivered iPSCs disrupt the natural repair response of endogenous MPCs after bone injury

Higher Steaks raises $30m, rebrands as Uncommon

UK-based Higher Steaks has rebranded as Uncommon and raised $30 million in a series A round to scale production of cultivated pork using patent-pending technology it claims gives it a competitive edge by speeding up the cell differentiation process. The funding round was led by Balderton Capital and Lowercarbon Capital,…

Continue Reading Higher Steaks raises $30m, rebrands as Uncommon

Solved I was told this from a previous answer.iPSCs can be

I was told this from a previous answer. iPSCs can be derived from patients with specific diseases, enabling the study of genetic and epigenetic factors underlying the condition. This personalized approach allows researchers to compare patient-derived iPSCs to healthy control iPSCs, providing insights into disease mechanisms and identifying potential therapeutic…

Continue Reading Solved I was told this from a previous answer.iPSCs can be

Axol Bioscience collaborates with StrataStem to deliver stem cell based ‘clinical trial in a dish’ for Alzheimer’s disease

Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples. Harnessing its stem cell expertise, Axol will reprogram these patient samples into induced Pluripotent Stem Cells…

Continue Reading Axol Bioscience collaborates with StrataStem to deliver stem cell based ‘clinical trial in a dish’ for Alzheimer’s disease

Six cardiovascular companies that have made their name

Cardiovascular disease is a general term used to describe a disease that affects the heart and blood vessels. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, with statistics from 2019 stating that an estimated 17.9 million people died from some type of…

Continue Reading Six cardiovascular companies that have made their name

Axol and StrataStem link up for Alzheimer’s disease trial

Companies will incorporate cells and technology to create a ‘clinical trial in a dish’ Axol Bioscience – a stem cell technology provider – has reached an agreement with StrataStem to access and commercialise its collection of Alzheimer’s disease (AD) patient samples. Under the terms, Axol will reprogramme…

Continue Reading Axol and StrataStem link up for Alzheimer’s disease trial

Hypoimmune iPSCs escape immune detection

RESEARCH HIGHLIGHT 07 June 2023 Regenerative cell-based therapies derived from induced pluripotent stem cells (iPSCs) have the potential to treat diseases involving the loss of specialized cells, such as type 1 diabetes. However, the host immune response presents a critical impediment to achieving efficient survival, engraftment and long-term functionality of…

Continue Reading Hypoimmune iPSCs escape immune detection

GMP iPSC Production | uBriGene

uBriGene has years of experience in developing cell therapy products, manufacturing GMP cell therapy products and well-rounded QA and QC systems to meet regulatory requirements. We provide clients with CDMO services such as stem cell production technique development, manufacturing, quality testing, and IND application documentation. We provide one-stop services including…

Continue Reading GMP iPSC Production | uBriGene

Bioconductor – peco

DOI: 10.18129/B9.bioc.peco     This package is for version 3.13 of Bioconductor; for the stable, up-to-date release version, see peco. A Supervised Approach for **P**r**e**dicting **c**ell Cycle Pr**o**gression using scRNA-seq data Bioconductor version: 3.13 Our approach provides a way to assign continuous cell cycle phase using scRNA-seq data, and consequently,…

Continue Reading Bioconductor – peco

Global Human iPSCs Market 2023

The Global Human iPSCs Market from 2023 to 2029 worldwide study paper, which MarketsandResearch.biz recently published, was prepared with a beautiful blend of business knowledge, innovative ideas, realistic solutions, and current technology in order to provide a better customer experience. The report includes regional and international market statistics and forecasts…

Continue Reading Global Human iPSCs Market 2023

iPSCs ameliorate hypoxia-induced autophagy and atrophy in C2C12 myotubes via the AMPK/ULK1 pathway

Background: Duchenne muscular dystrophy (DMD) is an X-linked lethal genetic disorder for which there is no effective treatment. Previous studies have shown that stem cell transplantation into mdx mice can promote muscle regeneration and improve muscle function, however, the specific molecular mechanisms remain unclear. DMD suffers varying degrees of hypoxic…

Continue Reading iPSCs ameliorate hypoxia-induced autophagy and atrophy in C2C12 myotubes via the AMPK/ULK1 pathway

Senior Scientist/ Scientist, Bioinformatics at Fate Therapeutics, Inc.

Fate Therapeutics is looking for a Senior Scientist or Scientist with expertise in bioinformatics to join the Molecular Engineering team.    The primary focus for this position will be to independently develop, optimize, and implement NGS pipelines to support advancement of Fate’s gene editing platform. The position will also establish, modify,…

Continue Reading Senior Scientist/ Scientist, Bioinformatics at Fate Therapeutics, Inc.

iPSCs for Studying Infectious Diseases

1. The Application of iPSCs to Questions in Virology: A Historical Perspective 2. Transplantation Of iPSCs -Derived Neural Progenitor Cells Promotes Clinical Recovery and Repair in Response to Murine Coronavirus-Induced Neurologic Disease 3. iPSCs For Modeling Influenza Infection 4. Human Induced Pluripotent Stem Cells for Modeling of Herpes Simplex Virus…

Continue Reading iPSCs for Studying Infectious Diseases

Generation of pluripotent stem cells via protein transduction

Cite Li X., Zhang P., Wei C., Zhang Y. (2014). Generation of pluripotent stem cells via protein transduction. Int. J. Dev. Biol. 58: 21-27. doi.org/10.1387/ijdb.140007XL Related articles …

Continue Reading Generation of pluripotent stem cells via protein transduction

Design Principles of a Novel Construct for HBB Gene-Editing and Investigation of Its Gene-Targeting Efficiency in HEK293 Cells

Jaing, T.-H., Chang, T.-Y., Chen, S.-H., Lin, C.-W., Wen, Y.-C., & Chiu, C.-C. (2021). Molecular genetics of β-thalassemia: A narrative review. Medicine, 100(45), e27522. Article  CAS  PubMed  PubMed Central  Google Scholar  Rattananon, P., Anurathapan, U., Bhukhai, K., & Hongeng, S. (2021). The future of gene therapy for transfusion-dependent beta-thalassemia: The…

Continue Reading Design Principles of a Novel Construct for HBB Gene-Editing and Investigation of Its Gene-Targeting Efficiency in HEK293 Cells

Fujifilm Life Sciences to Showcase Innovative and Comprehensive Solutions Supporting Advanced Therapies at BIO 2023

CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) — Fujifilm Life Sciences, a broad portfolio of Fujifilm Group operations offering products, services and comprehensive solutions that span support for all stages of therapeutic development from discovery through to commercialization, today announced that it will showcase its offerings across the therapeutics development…

Continue Reading Fujifilm Life Sciences to Showcase Innovative and Comprehensive Solutions Supporting Advanced Therapies at BIO 2023

iPSCs Manufacturing Services Market Future Trends and Scope Analysis Report 2023-2030

PRESS RELEASE Published June 1, 2023 InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled “Global iPSCs Manufacturing Services Market  (By Application (Research Products, Drug Development & Discovery, Cellular Therapy, Toxicology Screening, Personalized Medicine, Disease Modelling, Stem Cell Banking, Emerging Applications), End-User(Pharmaceutical & Biotechnology Companies,…

Continue Reading iPSCs Manufacturing Services Market Future Trends and Scope Analysis Report 2023-2030

Parkinson’s Disease Drug Slows ALS Progression in Clinical Trial

An early clinical trial headed by researchers at Keio University School of Medicine has shown that the Parkinson’s disease drug ropinirole is safe to use in patients with the fatal motor neuron disease amyotrophic lateral sclerosis (ALS), and delayed disease progression by an average of 27.9 weeks. The study demonstrated…

Continue Reading Parkinson’s Disease Drug Slows ALS Progression in Clinical Trial

Parkinson’s disease drug ropinirole safely slows the progression of amyotrophic lateral sclerosis, finds clinical trial

Photo of iPSCs-derived Motor neurons derived from an ALS patient. Credit: Morimoto et al/Cell Stem Cell Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a fatal motor neuron disease that causes people to gradually lose control of their muscles. There is no cure, and current treatments focus…

Continue Reading Parkinson’s disease drug ropinirole safely slows the progression of amyotrophic lateral sclerosis, finds clinical trial

Blockade of mGluR5 in Astrocytes Derived From Human iPSCs Modulates Astrocytic Function and Increases Phagocytosis[v1]

Preprint Article Version 1 This version is not peer-reviewed , , , , * Version 1 : Received: 30 May 2023 / Approved: 1 June 2023 / Online: 1 June 2023 (03:24:28 CEST) De Lima, I.B.Q.; Cardozo, P.L.; Fahel, J.S.; Lacerda, J.P.S.; Ribeiro, F.M. Blockade of mGluR5 in Astrocytes Derived…

Continue Reading Blockade of mGluR5 in Astrocytes Derived From Human iPSCs Modulates Astrocytic Function and Increases Phagocytosis[v1]

Transfer learning enables predictions in network biology

Vaswani, A. et al. Attention is all you need. Preprint at doi.org/10.48550/arXiv.1706.03762 (2017). Devlin, J., Chang, M. W., Lee, K. & Toutanova, K. BERT: pre-training of deep bidirectional transformers for language understanding. In Proc. 2019 Conference North American Chapter of the Association for Computational Linguistics: Human Language Technologies Vol. 1…

Continue Reading Transfer learning enables predictions in network biology

ElevateBio raises $401M for cell and gene therapies

ElevateBio, LLC (ElevateBio), a technology-driven company focused on cell and gene therapies, has closed its $401 million Series D financing. “We have made significant strides in scaling our technologies and end-to-end capabilities in our pursuit to become the world’s most indispensable cell and gene therapy technology company. We are thrilled…

Continue Reading ElevateBio raises $401M for cell and gene therapies

iPSC Characterization Kit Market Future Trends and Scope Analysis Report 2023-2030

PRESS RELEASE Published May 31, 2023 InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Value-Based Healthcare Services Market By Type (Alkaline Phosphatase Staining Assay, Pluripotency Markers (Protein) And Pluripotency Markers (Mrna)), Application (Cancer Research Center, Pathology Laboratory, Academic And Research, Contract Research Organizations…

Continue Reading iPSC Characterization Kit Market Future Trends and Scope Analysis Report 2023-2030

Integrated Resources, Inc ( IRI ) hiring Associate Scientist-iPSCs in Cambridge, Massachusetts, United States

Job Description: Senior Associate Scientist, Neuroscience Discovery Biology(100% on-site) seeks a highly motivated Associate Scientist to join the Stem Cell and Disease Modeling team in the Neuroscience Thematic Research Center (NTRC). The newly developed NTRC is dedicated to the discovery of new treatments for neurodegenerative diseases such as Alzheimers and…

Continue Reading Integrated Resources, Inc ( IRI ) hiring Associate Scientist-iPSCs in Cambridge, Massachusetts, United States

The Future of Regenerative Medicine: Exploring the Induced Pluripotent Stem Cell Market

The future of medicine is rapidly changing, and one area that is gaining momentum is regenerative medicine. With the ability to repair and regenerate damaged tissues and organs, regenerative medicine holds the promise of providing effective treatments for a wide range of diseases and injuries. One of the most exciting…

Continue Reading The Future of Regenerative Medicine: Exploring the Induced Pluripotent Stem Cell Market

DNA Polymerases Market is anticipated to cross worth of US$ 647.5 Million by growing at a CAGR of 6.2% during forecast 2023 to 2033

Future Market Insights Global and Consulting Pvt. Ltd. With a projected compound annual growth rate (CAGR) of 9.4% over the coming years, the DNA polymerase market in China is set to experience substantial growth. The increasing demand for customized DNA polymerase and the advancements in next-generation DNA sequencing technologies are…

Continue Reading DNA Polymerases Market is anticipated to cross worth of US$ 647.5 Million by growing at a CAGR of 6.2% during forecast 2023 to 2033

Propensity of Patient-Derived iPSCs for Retinal Differentiation: Implications for Autologous Cell Replacement

Prior to use, newly generated induced pluripotent stem cells (iPSC) should be thoroughly validated. While excellent validation and release testing assays designed to evaluate potency, genetic integrity, and sterility exist, they do not have the ability to predict cell type-specific differentiation capacity. Selection of iPSC lines that have limited capacity…

Continue Reading Propensity of Patient-Derived iPSCs for Retinal Differentiation: Implications for Autologous Cell Replacement

iPSCs and Neurological Diseases: Advancements and Challenges

Birey, F., Andersen, J., Makinson, C. D., Islam, S., Wei, W., Huber, N., … Paşca, S. P. (2017). Assembly of functionally integrated human forebrain spheroids. Nature, 545(7652), 54–59. doi:10.1038/nature22330 doi.org/10.1038/nature22330 Desbordes, S. C., & Studer, L. (2012). Adapting human pluripotent stem cells to high-throughput and high-content screening. Nature Protocols, 8(1),…

Continue Reading iPSCs and Neurological Diseases: Advancements and Challenges

Gates Center Stem Cell Biobank and Disease Modeling Core

Stem Cell Biobank and Disease Modeling Core Overview   The Stem Cell Biobank and Disease Modeling Core (SCB&DM core) offers complete services related to the production of high quality human induced pluripotent stem cells (iPSCs) from patient-derived somatic cells and genetic engineering of iPSCs.  The core employs a patent-pending, RNA-based methodology to…

Continue Reading Gates Center Stem Cell Biobank and Disease Modeling Core

Creative Biolabs Accelerates the Development of Innovative Cancer Treatment Strategies

PRESS RELEASE Published May 26, 2023 Creative Biolabs is committed to accelerating the development of innovative strategies for cancer treatment, driven by its vision of creating a healthier world. To facilitate cancer treatment research, the company has launched a range of services, including ICI development services and iPSC-derived cell development…

Continue Reading Creative Biolabs Accelerates the Development of Innovative Cancer Treatment Strategies

iPSCs in Tissue Engineering – 1st Edition

Alexander Birbrair Dr. Alexander Birbrair received his bachelor’s biomedical degree from Santa Cruz State University in Brazil. He completed his PhD in Neuroscience, in the field of stem cell biology, at the Wake Forest School of Medicine under the mentorship of Osvaldo Delbono. Then, he joined as a postdoc in…

Continue Reading iPSCs in Tissue Engineering – 1st Edition

Cartherics to present at the 2023 BIO International Convention

Melbourne, Australia, 24 May 2023 – Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it is presenting at the upcoming 2023 BIO International Convention June 5-8, 2023, in Boston, Massachusetts. CEO Prof. Alan Trounson will meet with senior biotech executives, business development leaders…

Continue Reading Cartherics to present at the 2023 BIO International Convention

Century Therapeutics: Revolutionizing Cancer Treatment with Allogeneic Cell Therapy.

Looking for a biotechnology company that could potentially change the game in cancer treatment? Look no further than Century Therapeutics, Inc. (NASDAQ: IPSC). With its cutting-edge allogeneic cell therapies aimed at treating both solid tumor and hematological malignancies, Century Therapeutics has captured the attention of nine out of ten rating…

Continue Reading Century Therapeutics: Revolutionizing Cancer Treatment with Allogeneic Cell Therapy.

Cartherics to present at 2023 BIO International Convention in Boston

Prof. Alan Trounson will meet with senior biotech executives, business development leaders and investors to discuss the company’s technology and development program. He will also be presenting at 3:45pm on Wednesday 7 June, detailing Cartherics’ pipeline, R&D activities, business objectives, and investment goals – with a view to engaging with…

Continue Reading Cartherics to present at 2023 BIO International Convention in Boston

Stem Cell Therapy Market 2023 Growth, Trend, Share, and Forecast till 2030

PRESS RELEASE Published May 22, 2023 [125 Pages] In 2023, Stem Cell Therapy Market Size is projected to reach Multimillion USD by 2028, In comparison to 2023. Stem Cell Therapy MarketInsights 2023 With “Stem Cell Therapy market size was valued at USD 12932.56 million in 2022 and is expected to…

Continue Reading Stem Cell Therapy Market 2023 Growth, Trend, Share, and Forecast till 2030

Fate Therapeutics: The Future Remains Cloudy (NASDAQ:FATE)

urbazon/E+ via Getty Images Life is what happens to us while we are making other plans.” – Allen Saunders. Today, we revisit Fate Therapeutics, Inc. (NASDAQ:FATE). This is a name I have not taken an in-depth look at in years but comes up from time to time on Live Chat….

Continue Reading Fate Therapeutics: The Future Remains Cloudy (NASDAQ:FATE)

Postdoctoral Fellow- Ultanir Lab job with Francis Crick Institute

Postdoctoral Fellow – Ultanir Lab Reporting to: Sila Ultanir, Group Leader Contact term: This is a full-time, fixed term (4-year) position on Crick terms and conditions of employment.   The Research Group An exciting opportunity for a motivated postdoctoral scientist to join Kinases and Brain Development laboratory www.crick.ac.uk/research/labs/sila-ultanir at the…

Continue Reading Postdoctoral Fellow- Ultanir Lab job with Francis Crick Institute

Automating CRISPR-based cell line development

The growing demand for more rapid high-throughput cell-line development and improved screening in the pharmaceutical space is motivating research facilities and companies to automate their labs. Though robotics has been present in some laboratories for around four decades, it is becoming increasingly common. It helps to free researchers of repetitive…

Continue Reading Automating CRISPR-based cell line development

Multi-faceted CRISPR/Cas technological innovation aspects in the framework of 3P medicine

Golubnitschaja O, Baban B, Boniolo G, Wang W, Bubnov R, Kapalla M, et al. Medicine in the early twenty-first century: paradigm and anticipation – EPMA position paper 2016. EPMA J. 2016;7:23. Article  PubMed  PubMed Central  Google Scholar  Kropp M, Golubnitschaja O, Mazurakova A, Koklesova L, Sargheini N, Vo T-TKS, et…

Continue Reading Multi-faceted CRISPR/Cas technological innovation aspects in the framework of 3P medicine

Snapshot: What are induced pluripotent stem cells (iPSCs)?

Induced pluripotent stem cells or iPSCs are adult stem cells that can be transformed into different types of tissues or organs. This research can be used to study different disease mechanisms. Many multicellular organisms like us come from a fertilized egg cell, the zygote, which divides into more and more…

Continue Reading Snapshot: What are induced pluripotent stem cells (iPSCs)?

Framework for understanding cell organisation and variation

From a database of more than 200,000 high-resolution, three-dimensional images of human induced pluripotent stem cells, researchers have devised a model to quantify cell shape and internal organization. Susanne Rafelski, Deputy Director of the Allen Institute for Cell Science, revealed details of their study to Drug Target Review. A recently…

Continue Reading Framework for understanding cell organisation and variation

Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Senti Biosciences, Inc. Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages SOUTH SAN FRANCISCO, Calif., May 20, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies…

Continue Reading Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Genetically corrected, iPSC-derived epithelial sheets to treat RDEB

Researchers at Stanford have developed a targeted gene therapy approach to treat patients with recessive dystrophic epidermolysis bullosa (RDEB). Epidermolysis bullosa (EB) represents a group of debilitating inherited skin disorders in which blisters develop after minor trauma to the skin. Symptoms and severity depend on type of EB. RDEB is…

Continue Reading Genetically corrected, iPSC-derived epithelial sheets to treat RDEB

Revvity announces license agreement with AstraZeneca for Next-Generation Base Editing Technology

Revvity, Inc. on Friday announced a new license agreement with AstraZeneca for the technology underlying its Pin-point base editing system, a next-generation modular gene editing platform with a strong safety profile. “Our fundamental goal for the Pin-point platform is to translate the technology from pre-clinical research into the clinic, and…

Continue Reading Revvity announces license agreement with AstraZeneca for Next-Generation Base Editing Technology

Allen Institute takes on a supporting role in experiment to grow stem cells in space

A live colony of human induced pluripotent stem cells fills the screen of a microscope. (Allen Institute Photo) Space: The final frontier … for stem cells? Seattle’s Allen Institute for Cell Science says cells from its collection are going into space for the first time on a private mission to…

Continue Reading Allen Institute takes on a supporting role in experiment to grow stem cells in space

Recipe for Making Blood Vessel Cells From Patient Stem Cells Published

Register for free to listen to this article Thank you. Listen to this article using the player above. ✖ Want to listen to this article for FREE? Complete the form below to unlock access to ALL audio articles. Researchers at NIH’s National Eye Institute have published a…

Continue Reading Recipe for Making Blood Vessel Cells From Patient Stem Cells Published

Researchers Publish a Detailed Protocol for Making Three Cell Types From iPSCs

Reviewed by Danielle Ellis, B.Sc.May 17 2023 Researchers at NIH’s National Eye Institute have published a detailed protocol for making three cell types that are key components to form blood vessels and capillaries. The technique enables researchers to make tissues for study and potentially for future treatments. This protocol generates…

Continue Reading Researchers Publish a Detailed Protocol for Making Three Cell Types From iPSCs

Impact of the Overexpression of the Tyrosine Kinase Receptor RET in the Hematopoietic Potential of Induced Pluripotent Stem Cells (iPSCs) [v1]

Preprint Article Version 1 This version is not peer-reviewed Version 1 : Received: 16 May 2023 / Approved: 17 May 2023 / Online: 17 May 2023 (13:49:58 CEST) Marcoux, P.; Imeri, J.; Desterke, C.; Latsis, T.; Chaker, D.; Hugues, P.; Bennaceur-Griscelli, A.; Turhan, A.G. Impact of the Overexpression of the…

Continue Reading Impact of the Overexpression of the Tyrosine Kinase Receptor RET in the Hematopoietic Potential of Induced Pluripotent Stem Cells (iPSCs) [v1]

Nerve Repair and Regeneration Market Trend 2023 Predicted to Surpass USD $12.3 Bn by 2030

As per the report, the global nerve repair and regeneration industry generated $6.6 billion in 2020, and is expected to reach $12.3 billion by 2030, growing at a CAGR of 6.5% from 2021 to 2030. The study analyzes the important strategies, drivers, competition, market dynamics, size, and important investment regions. Key Takeaways: Market…

Continue Reading Nerve Repair and Regeneration Market Trend 2023 Predicted to Surpass USD $12.3 Bn by 2030

Publication of a Recipe on Creating Blood Vessel Cells from Stem Cells of Patients

– Advertisement – The National Eye Institute has published a protocol for making three types of cells that are crucial in forming blood vessels and capillaries. The technique uses human induced pluripotent stem cells (iPSCs) and enables researchers to create tissues for study and potential treatment of various diseases, including…

Continue Reading Publication of a Recipe on Creating Blood Vessel Cells from Stem Cells of Patients

Scientists publish recipe for making blood vessel cells from patient stem cells

Graphical abstract. Credit: STAR Protocols (2023). DOI: 10.1016/j.xpro.2023.102292 Researchers at NIH’s National Eye Institute have published a detailed protocol for making three cell types that are key components to form blood vessels and capillaries. The technique enables researchers to make tissues for study and potentially for future treatments. “This protocol…

Continue Reading Scientists publish recipe for making blood vessel cells from patient stem cells

NEI Scientists publish recipe for making blood vessel cells from patient stem cells

Newswise — Researchers at NIH’s National Eye Institute have published a detailed protocol for making three cell types that are key components to form blood vessels and capillaries. The technique enables researchers to make tissues for study and potentially for future treatments. “This protocol generates vascular endothelial cells, pericytes, and…

Continue Reading NEI Scientists publish recipe for making blood vessel cells from patient stem cells

axoLines – cell lines derived from human iPSCs

Commercially available and consented iPSC lines We have a commercial library of 70 iPSCs from a range of patient and healthy donors. The cell lines include those from healthy donors and those with:  Alzheimer’s Disease  Parkinson’s Disease  Amyotrophic Lateral Sclerosis (ALS)  Frontotemporal Dementia  Friedreich’s Ataxia  Huntington’s Disease  Our axoLinesTM iPSCs are…

Continue Reading axoLines – cell lines derived from human iPSCs

In Vivo Delivery of Therapeutic Molecules by Transplantation of Genome-Edited Induced Pluripotent Stem Cells

Human induced pluripotent stem cells (iPSCs) have already been used in transplantation therapies. Currently, cells from healthy people are transplanted into patients with diseases. With the rapid evolution of genome editing technology, genetic modification could be applied to enhance the therapeutic effects of iPSCs, such as the introduction of secreted…

Continue Reading In Vivo Delivery of Therapeutic Molecules by Transplantation of Genome-Edited Induced Pluripotent Stem Cells

iPSCs Manufacturing Services Market Future Trends and Scope Analysis Report 2023-2031

PRESS RELEASE Published May 15, 2023 InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the ” Global iPSCs Manufacturing Services Market by (Applications (Research Products, Drug Development & Discovery, Cellular Therapy, Toxicology Screening, Personalized Medicine, Disease Modelling, Stem Cell Banking, and Emerging Applications), End-user (Pharmaceutical…

Continue Reading iPSCs Manufacturing Services Market Future Trends and Scope Analysis Report 2023-2031

Research Collaboration for Mekonos, Bit.bio to Advance Cell Engineering

This approach is defined as being used to express transcription factor combinations to reprogram human induced pluripotent stem cells (iPSCs). Mekonos, Inc. announced a new research collaboration with bit.bio on May 4, 2023 to test and optimize non-viral delivery of bit.bio’s patented safe harbor gene-targeting approach. This approach is defined…

Continue Reading Research Collaboration for Mekonos, Bit.bio to Advance Cell Engineering

AT7867 promotes pancreatic progenitor differentiation of human iPSCs and accelerates diabetes reversal

Abstract Generation of pure pancreatic progenitor cells (PPs) is critical for clinical translation of stem cell derived islets. Herein, we performed PP differentiation with and without AKT/P70 inhibitor AT7867 and characterized the resulting cells at protein and transcript level in vitro and in vivo upon transplantation into diabetic mice. AT7867…

Continue Reading AT7867 promotes pancreatic progenitor differentiation of human iPSCs and accelerates diabetes reversal

Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant

Ethics statement All experiments with hamsters were performed in accordance with the Science Council of Japan’s Guidelines for the Proper Conduct of Animal Experiments. The protocols were approved by the Institutional Animal Care and Use Committee of National University Corporation Hokkaido University (approval ID: 20-0123 and 20-0060). All protocols involving…

Continue Reading Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant

Mobile element variation contributes to population-specific genome diversification, gene regulation and disease risk

Development and benchmarking of MEGAnE Accurate variant genotyping is required for statistical genetics. To enable both discovery and accurate MEV genotyping from genomes studied using short reads, we developed a new bioinformatic tool, mobile element genotype analysis environment (MEGAnE; Supplementary Note). Compared to SVs resolved by long reads, MEGAnE discovers…

Continue Reading Mobile element variation contributes to population-specific genome diversification, gene regulation and disease risk

Axiom will take stem cells into space and produce them in large quantities

For the first time, astronauts will develop induced pluripotent stem cells in microgravity. — Cedars Sinai Madrid, 10 May. (Europe Press) – Cedars-Sinai researchers will explore whether microgravity can be eased by sending stem cells into space. and makes the production of large volumes of stem cells more efficient. The…

Continue Reading Axiom will take stem cells into space and produce them in large quantities

For the first time they will cultivate stem cells in space

Induced pluripotent stem cells (or iPSCs) are a type of stem cell that can develop into the three main groups of cells that make up the human body. They can be obtained from a person’s blood or skin, and their importance in research is enormous. On the one hand, they…

Continue Reading For the first time they will cultivate stem cells in space

Astronauts travelling to the ISS will cultivate stem cells in space for the first time

USA: Astronauts travelling to the International Space Station (ISS) on Axiom Space’s Ax-2 mission, scheduled to launch on May 21, will cultivate stem cells for the first time in space. In particular, induced pluripotent stem cells (iPSCs), which are cells with the capacity for self-renewal and development into the three major…

Continue Reading Astronauts travelling to the ISS will cultivate stem cells in space for the first time

Selection of iPSCs without mtDNA deletion for autologous cell therapy in a patient with Pearson syndrome

Screening for genetic defects in the cells should be examined for clinical application. The Pearson syndrome (PS) patient harbored nuclear mutations in the POLG and SSBP1 genes, which could induce systemic large-scale mitochondrial genome (mtDNA) deletion. We investigated iPSCs with mtDNA deletions in PS patient and whether deletion levels could…

Continue Reading Selection of iPSCs without mtDNA deletion for autologous cell therapy in a patient with Pearson syndrome

Research Technologist – Stem Cell Core – San Francisco

Category:ScienceLab/Area:Stem Cell Core Description: The Stem Cell Core is a state-of-the-art facility providing comprehensive pluripotent stem cell related services (standard and customized), training and consultations. Our focus includes reprogramming of somatic cells into iPSCs, differentiation of iPSCs into various cell lineages and genome editing in iPSCs. Our mission is to…

Continue Reading Research Technologist – Stem Cell Core – San Francisco

Ax-2 mission astronauts will grow first stem cells in space

Ax-2 mission astronauts will grow first stem cells in space May 10, 2023, 11:45 am 3 min read The Ax-2 mission will launch no earlier than May 21. Representative image (Photo credit: ESA) For the first time, stem cells will be grown in space, by astronauts flying to the International…

Continue Reading Ax-2 mission astronauts will grow first stem cells in space

Stem cells to be launched into space

Cedars-Sinai investigators, in collaboration with Axiom Space, are planning on sending stem cells into space in order to explore whether microgravity can make it easier and more efficient to produce large batches of stem cells. This is the first of a series of missions funded by NASA where, for the…

Continue Reading Stem cells to be launched into space

5 cell therapy companies you should know about

Cell therapy has come a long way in recent years, with many biotech companies now specializing in the development of cell therapies to treat various diseases. In this article we take a look at five of those companies. Cell therapy refers to the transplantation of human cells in order to…

Continue Reading 5 cell therapy companies you should know about

Sana Biotechnology Announces P – GuruFocus.com

Hypoimmune-modified allogeneic iPSCs evade immune response and rejection without immunosuppression in non-human primate model Long-term survival and immune evasion of hypoimmune-modified allogeneic iPSCs at least equivalent to survival of autologous iPSCs CD47 overexpression provided robust protection of hypoimmune-modified allogeneic cells from killing by the innate immune system versus other engineering…

Continue Reading Sana Biotechnology Announces P – GuruFocus.com

Senti Bio Announces First Quarter 2023 Results and Pipeline

– New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission and clearance in 2H 2023 – – Initial collaboration data with BlueRock and Spark to be presented at ASGCT, validating that Senti’s Gene Circuit enabled cell platform…

Continue Reading Senti Bio Announces First Quarter 2023 Results and Pipeline

SpaceX Ax-2 astronaut mission will grow 1st stem cells in space

Scientists will send stem cells to space in early May to investigate the effect of weak gravity or “microgravity” in space on stem cells.  The induced pluripotent stem cells (iPSCs), a type of stem cell that can develop into the three primary groups of cells that make up a human…

Continue Reading SpaceX Ax-2 astronaut mission will grow 1st stem cells in space

Asia Pacific Stem Cell Therapy Market Set for More Growth From 2023 to 2031

PRESS RELEASE Published May 9, 2023 The Asia Pacific Stem Cell Therapy Market is poised for substantial growth in the coming years, with a projected compound annual growth rate (CAGR) of 10.29% between 2023 and 2031. This growth is expected to drive the market value up to US$ 3,420.05 Mn…

Continue Reading Asia Pacific Stem Cell Therapy Market Set for More Growth From 2023 to 2031

Induced Pluripotent Stem Cells Market Facts, Future Scenarios, Growth and Analytical Insights 2032

Induced Pluripotent Stem Cells Market 2032 Induced pluripotent stem cells market comprehensive analysis of factors that drive and restrict. PORTLAND, OREGON, UNITED STATES, May 8, 2023 /EINPresswire.com/ — Pluripotent stem cells are embryonic stem cells that have the potential to form all adult cell types and help in repairing of…

Continue Reading Induced Pluripotent Stem Cells Market Facts, Future Scenarios, Growth and Analytical Insights 2032

Sana Biotechnology Announces Preclinical Data Published in

Hypoimmune-modified allogeneic iPSCs evade immune response and rejection without immunosuppression in non-human primate model Long-term survival and immune evasion of hypoimmune-modified allogeneic iPSCs at least equivalent to survival of autologous iPSCs CD47 overexpression provided robust protection of hypoimmune-modified allogeneic cells from killing by the innate immune system versus other engineering…

Continue Reading Sana Biotechnology Announces Preclinical Data Published in

Solved htips:ilwww.nature.com/articlesis41467-022-29967-1 A | Chegg.com

Transcribed image text: htips:ilwww.nature.com/articlesis41467-022-29967-1 A 2022 paper “Periodic formation of epithelial somites from human pluripotent stem cells” shows that they could treat induced pliniplotent stem cells with factors that promoted somite formation. Fig. 1: Generation and characterization of human somitoids. a Human somitoid protocol b c 350 human iPSCs/well U-bottom…

Continue Reading Solved htips:ilwww.nature.com/articlesis41467-022-29967-1 A | Chegg.com

CGMP-Compliant iPSC Manufacturing of Differentiated Cells

Date: Tuesday, May 30, 2023 Time: 9:00AM EST / 2:00PM BST / 3:00PM CEST Abstract: Despite the potential benefits of induced pluripotent stem cells (iPSCs) to differentiate into multiple cell lineages and serve in regenerative medicine and immune cell therapy, CGMP-compatible implementation of the necessary methodologies remains challenging. At the…

Continue Reading CGMP-Compliant iPSC Manufacturing of Differentiated Cells

Organoids containing neural-like cells derived from chicken iPSCs respond to poly:IC through the RLR family

. 2023 May 4;18(5):e0285356. doi: 10.1371/journal.pone.0285356. eCollection 2023. Affiliations Expand Affiliations 1 Biodiversity Division, National Institute for Environmental Studies, Onogawa, Tsukuba, Ibaraki, Japan. 2 Graduate School of Science and Engineering, Iwate University, Ueda, Morioka-city, Japan. Free article Item in Clipboard Masafumi Katayama et al. PLoS One. 2023. Free article Show details…

Continue Reading Organoids containing neural-like cells derived from chicken iPSCs respond to poly:IC through the RLR family

Eterna Therapeutics Buys Allogeneic Immuno-Oncology Platform from Exacis

  By Healthcare Edge Editorial Staff Eterna Therapeutics Inc. (Nasdaq: ERNA) said it has acquired Exacis Biotherapeutics’ global immuno-oncology platform, which includes their pipeline of engineered cell therapy programs for hematologic and solid tumors. The acquisition gives Eterna an exclusive global license to produce an unlimited number of mRNA-engineered natural killer (NK)…

Continue Reading Eterna Therapeutics Buys Allogeneic Immuno-Oncology Platform from Exacis

iPSC Characterization Kit Market Robust Expansion is expected to 2030

PRESS RELEASE Published May 3, 2023 InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Value-Based Healthcare Services Market By Type (Alkaline Phosphatase Staining Assay, Pluripotency Markers (Protein) And Pluripotency Markers (Mrna)), Application (Cancer Research Center, Pathology Laboratory, Academic And Research, Contract Research Organizations…

Continue Reading iPSC Characterization Kit Market Robust Expansion is expected to 2030

Eterna acquires allogeneic immuno-oncology platform from Exacis

Eterna Therapeutics Inc. has announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics. The acquisition complements Eterna’s core business with a pipeline of allogeneic immuno-oncology products under development for the treatment of hematologic and solid tumors and provides Eterna with an exclusive global license to produce an unlimited…

Continue Reading Eterna acquires allogeneic immuno-oncology platform from Exacis

iPSCs Manufacturing Services Market | Know the Latest Innovations in the Industry

PRESS RELEASE Published May 2, 2023 InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled “Global iPSCs Manufacturing Services Market  (By Application (Research Products, Drug Development & Discovery, Cellular Therapy, Toxicology Screening, Personalized Medicine, Disease Modelling, Stem Cell Banking, Emerging Applications), End-User(Pharmaceutical & Biotechnology Companies,…

Continue Reading iPSCs Manufacturing Services Market | Know the Latest Innovations in the Industry

Eterna Therapeutics Acquires Exacis’ Allogeneic Immuno-Oncology Platform

Eterna Therapeutics acquired the global immuno-oncology platform of Exacis Biotherapeutics. Eterna officials say the acquisition complements the company’s core business with a pipeline of allogeneic immuno-oncology products under development for the treatment of hematologic and solid tumors. The deal also provides Eterna with an exclusive global license to produce an…

Continue Reading Eterna Therapeutics Acquires Exacis’ Allogeneic Immuno-Oncology Platform

BioCentriq and panCELLa execute research agreement to study stem cell-derived Natural Killer cell expansion technology

Agreement evaluates induced pluripotent stem cell-derived feeder cells to improve NK manufacturing NEWARK, N.J. and SEATTLE, May 2, 2023 /PRNewswire/ — BioCentriq, Inc. and panCELLa, a Pluristyx Company, announced that they have signed a research agreement designed to evaluate the ability of panCELLa’s genetically-engineered, induced Pluripotent Stem Cell (iPSC)-derived, feeder…

Continue Reading BioCentriq and panCELLa execute research agreement to study stem cell-derived Natural Killer cell expansion technology

Editas Medicine Announces Publication in Nature

CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the journal Nature Biotechnology published the comprehensive data from a study of the proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) gene editing technology. Despite major progress in achieving…

Continue Reading Editas Medicine Announces Publication in Nature

Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data

Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the journal Nature Biotechnology published the comprehensive data from a study of the proprietary…

Continue Reading Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data

Trends and prospects in mitochondrial genome editing

Mitochondria, double membrane-bound organelles referred to as the “powerhouses of the cell”, play an indispensable role in eukaryotic cells, as they are associated with metabolism1,2 and orchestrate a variety of other cellular functions, such as apoptosis, cell pluripotency, autophagy, calcium homeostasis, and innate immunity3,4,5,6,7,8,9. The mitochondrial genome is independent and…

Continue Reading Trends and prospects in mitochondrial genome editing

Functional genomics in stroke: current and future applications of iPSCs and gene editing to dissect the function of risk variants | BMC Cardiovascular Disorders

Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20:1–26. Article  Google Scholar  Wolters FJ, Arfan IM. Epidemiology of Vascular…

Continue Reading Functional genomics in stroke: current and future applications of iPSCs and gene editing to dissect the function of risk variants | BMC Cardiovascular Disorders

Functional genomics in stroke: current and future applications of iPSCs and gene editing to dissect the function of risk variants

Review doi: 10.1186/s12872-023-03227-6. Affiliations Expand Affiliation 1 Department of Clinical Neurosciences, Victor Phillip Dahdaleh Heart & Lung Research Institute, Papworth Road, Cambridge Biomedical Campus, University of Cambridge, Cambridge, CB2 0BB, UK. ag686@cam.ac.uk. Item in Clipboard Review Alessandra Granata. BMC Cardiovasc Disord. 2023. Show details Display options Display options Format AbstractPubMedPMID…

Continue Reading Functional genomics in stroke: current and future applications of iPSCs and gene editing to dissect the function of risk variants

Century Therapeutics: A Promising Allogeneic Cell Therapy Company with Strong Growth Prospects

Century Therapeutics: An Allogeneic Cell Therapy Company with Good Prospects Century Therapeutics, Inc. (NASDAQ:IPSC) is presently enjoying a positive outlook from eleven research firms covering the company, according to Bloomberg Ratings. The research firms have assigned an average recommendation of “Moderate Buy” for its shares, indicating the potential for good…

Continue Reading Century Therapeutics: A Promising Allogeneic Cell Therapy Company with Strong Growth Prospects

iPSCs for modeling familial hypercholesterolemia type II A

In this chapter, we will first introduce the causes of familial hypercholesterolemia disease, available treatments, and cell and animal models. As they keep the mutations inside their genome after reprogramming, patient’s specific human-induced pluripotent stem cells (hiPSCs) seem to be the most relevant cells to model familial hypercholesterolemia. In a…

Continue Reading iPSCs for modeling familial hypercholesterolemia type II A

Developing new ways to repair tendons

Cedars-Sinai investigators are working to develop a more effective treatment for one of the most common and hard-to-heal musculoskeletal injuries: torn tendons.  Investigators led by Dmitriy Sheyn, PhD, assistant professor in the Cedars-Sinai Board of Governors Regenerative Medicine Institute, and the departments of Orthopaedics, Surgery and Biomedical Sciences at Cedars-Sinai, are studying how…

Continue Reading Developing new ways to repair tendons

Plasticell LambdaGen team on stem cells

The $650,000 partnership hopes to reduce manufacturing cost and increase immunoactivity for iPSC-derived allogenic cancer immunotherapies. The strategic partnership between UK-based Plasticell and Singapore-based LambdaGen will develop induced pluripotent stem cell (iPSCs) derived chimeric antigen receptor-natural killer (CAR-NK) allogenic cancer immunotherapies. The collaboration is funded by EUREKA GlobalStars, an international…

Continue Reading Plasticell LambdaGen team on stem cells

Stem Cell Manufacturing Market Booms Acknowledge to Pharma and Biotech Innovations

PRESS RELEASE Published April 28, 2023 As per the study initiated by Evolve Business Intelligence, the global Stem Cell Manufacturing market size accounted for USD 12.10 Billion in 2022, growing at a CAGR of 9.41% from 2023 to 2033. Stem cell manufacturing involves the production of stem cells on a…

Continue Reading Stem Cell Manufacturing Market Booms Acknowledge to Pharma and Biotech Innovations

Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of AML

Dr Eirini Papapetrou speaks to ecancer about her study which found that patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of human acute myeloid leukaemia. This study created a reprogramming method called “Complete Capture of Mutational Burden” (CCoMB). This method combines comprehensive genetic characterisation of the starting sample…

Continue Reading Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of AML

An Efficient 2D Protocol for Differentiation of iPSCs into Mature Postmitotic Dopaminergic Neurons: Application for Modeling Parkinson’s Disease

. 2023 Apr 14;24(8):7297. doi: 10.3390/ijms24087297. Olga S Lebedeva  1   2 , Elena I Sharova  1 , Dmitriy A Grekhnev  3 , Liubov O Skorodumova  1 , Irina V Kopylova  1 , Ekaterina M Vassina  4 , Arina Oshkolova  3 , Iuliia V Novikova  3 , Alena V Krisanova  3 , Evgenii I Olekhnovich  1   2 , Vladimir…

Continue Reading An Efficient 2D Protocol for Differentiation of iPSCs into Mature Postmitotic Dopaminergic Neurons: Application for Modeling Parkinson’s Disease

Beyond Biotech podcast 43

This week’s podcast is sponsored by Scientist.com. The mainstream news in the past couple of months has picked up on artificial intelligence (AI). Not so much its uses, more the potential for conflict and fears over AI developing too quickly, or ‘taking over humanity.’ Debates have sprung up around deepfakes,…

Continue Reading Beyond Biotech podcast 43

Stem Cells and Regenerative Medicine: Biotech’s Impact on Health

PRESS RELEASE Published April 27, 2023 Stem cells are undifferentiated cells that can differentiate into various types of specialized cells in the body. They can self-renew and regenerate, making them unique and critical for developing, growing, and repairing tissues and organs in the body. Regenerative medicine is a field of…

Continue Reading Stem Cells and Regenerative Medicine: Biotech’s Impact on Health

Omicron variant’s growth, illness severity greatly reduced by heat: Japan-US research

This electron microscope photo shows the coronavirus’s omicron variant successfully isolated at the National Institute of Infectious Diseases. (Photo courtesy of the National Institute of Infectious Diseases.) TOKYO — In the process of mutation, the coronavirus’s omicron variant may have become…

Continue Reading Omicron variant’s growth, illness severity greatly reduced by heat: Japan-US research

Mass Spectrometry Imaging Reveals Early Metabolic Priming of Cell Lineage in Differentiating Human-Induced Pluripotent Stem Cells

Researchers have now used mass spectrometry imaging to study induced pluripotent stem cells (iPSCs) during the early stages of differentiation. A new study from Melissa L. Kemp, a researcher at Georgia Institute of Technology and Emory University in Atlanta, Georgia, USA, has used mass spectrometry imaging to reveal the metabolic…

Continue Reading Mass Spectrometry Imaging Reveals Early Metabolic Priming of Cell Lineage in Differentiating Human-Induced Pluripotent Stem Cells

Plasticell and LambdaGen form collaboration to develop iPSC-derived CARNK allogeneic cancer immunotherapies

Stevenage, 25th April 2023. Plasticell Ltd, a developer of stem cell technologies and advanced therapies, has announced today that it has entered into a strategic collaboration with Singapore-based LambdaGen. Together, the two companies will exploit genome editing technologies based on synthetic lambda integrases that allow specific insertion of large gene…

Continue Reading Plasticell and LambdaGen form collaboration to develop iPSC-derived CARNK allogeneic cancer immunotherapies

Plasticell and LambdaGen join hands to exploit genome editing technologies

Plasticell and LambdaGen to develop iPSC-derived CAR-NK allogeneic cancer immunotherapies UK-based firm Plasticell, a developer of stem cell technologies and advanced therapies, has entered into a strategic collaboration with Singapore-based LambdaGen. Together, the two companies will exploit genome editing technologies based on synthetic lambda integrases that allow specific insertion of…

Continue Reading Plasticell and LambdaGen join hands to exploit genome editing technologies